Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized Azacytidine and Bintrafusp Alfa for Pulmonary Metastases
NCT04648826Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine and bintrafusp alfa in cancer, sarcoma, melanoma and 2 more (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 3 weeks, Recommended Phase 2 Dose at 3 weeks and 3 more. Planned start Dec 2021; status: withdrawn.
02
Drugs
azacitidinebintrafusp alfa
03
Conditions
cancersarcomamelanomagerm cell tumor (GCT)carcinoma
Beyond the preview
Go deeper on NCT04648826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648826.